Stock Events

Stock Events

eFFECTOR Therapeutics 

€0.2400
0
+€0.00+0%Thursday 06:17

Statistics

Day High
0.24
Day Low
0.24
52W High
0.24
52W Low
0.24
Volume
90
Avg. Volume
0
Mkt Cap
1.13M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Jan 1Expected
Q4 0
-0.66
-0.33
0.01
0.34
Expected EPS
-0.6601560000000001
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
0Revenue
-32.97MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LWK.MU. It's not an investment recommendation.
Apple
6
AAPL
Realty Income
4
O
Amazon
4
AMZN
AMD
4
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap88.52B
Moderna is a leader in mRNA technology, which competes in the broader biotech space for treatments including cancer, where eFFECTOR also operates.
BioNTech
BNTX
Mkt Cap22.15B
BioNTech competes in the development of novel therapies for cancer, directly challenging eFFECTOR's focus on innovative cancer treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap22.1B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, a competing technology in the field of genetic medicine, where eFFECTOR's mRNA-focused therapies also aim to make an impact.
Ionis Pharmaceuticals
IONS
Mkt Cap7.23B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, offering a competitive stance in the same therapeutic areas as eFFECTOR.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap8.46B
Arrowhead Pharmaceuticals is involved in developing RNAi therapies for a variety of diseases, including cancer, making it a direct competitor.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics is at the forefront of CRISPR-Cas9 gene editing, a revolutionary technology that competes with eFFECTOR's therapeutic strategies.
Intellia Therapeutics
NTLA
Mkt Cap1.75B
Intellia Therapeutics is another key player in CRISPR-Cas9 gene editing, directly competing with eFFECTOR in the development of groundbreaking treatments.
Beam Therapeutics
BEAM
Mkt Cap2.81B
Beam Therapeutics focuses on base editing, a novel form of gene editing, presenting competition in the innovative treatment landscape where eFFECTOR operates.
Editas Medicine
EDIT
Mkt Cap410.06M
Editas Medicine is involved in gene editing technology, competing in the same space as eFFECTOR by aiming to develop unique treatments for diseases including cancer.

About

eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers. The company's primary investigational drug, Tomivosertib, is an orally administered small molecule that targets and inhibits MNK. This compound is currently undergoing a Phase 2b clinical study for patients diagnosed with metastatic non-small cell lung cancer. Furthermore, eFFECTOR is progressing with Zotatifin, another small-molecule therapeutic designed to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 2 clinical trials, exploring its efficacy in treating different solid tumors. A strategic alliance with Pfizer Inc. supports eFFECTOR's work on developing additional eIF4E inhibitors. Founded in 2012, eFFECTOR Therapeutics, Inc. maintains its operational base in Solana Beach, California.
Show More
CEO
Craig R. Jalbert
Employees
14
Country
United States
ISIN
US28202V2079
WKN
000A3ELKJ

Listings

MU
DE
LWK1.MU
MU
DE
LWK.MU
OTC Link
US
EFTR

0 Comments

Share your thoughts

FAQs

What is eFFECTOR Therapeutics stock price today?▼
The current price of LWK.MU is €0.24 EUR — it has increased by +0% in the past 24 hours. Watch eFFECTOR Therapeutics stock price performance more closely on the chart.
What is eFFECTOR Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange eFFECTOR Therapeutics stocks are traded under the ticker LWK.MU.
What is eFFECTOR Therapeutics market cap?▼
Today eFFECTOR Therapeutics has the market capitalization of 1.13M
What is eFFECTOR Therapeutics revenue for the last year?▼
eFFECTOR Therapeutics revenue for the last year amounts to 0 EUR.
What is eFFECTOR Therapeutics net income for the last year?▼
LWK.MU net income for the last year is -32.97M EUR.
How many employees does eFFECTOR Therapeutics have?▼
As of November 2, 2026, the company has 14 employees.
In which sector is eFFECTOR Therapeutics located?▼
eFFECTOR Therapeutics operates in the Health & Wellness sector.
When did eFFECTOR Therapeutics complete a stock split?▼
The last stock split for eFFECTOR Therapeutics was on January 12, 2024 with a ratio of 1:25.
Where is eFFECTOR Therapeutics headquartered?▼
eFFECTOR Therapeutics is headquartered in Solana Beach, United States.